key: cord-1028973-enkjcp8q authors: Panepinto, Julie A.; Brandow, Amanda; Mucalo, Lana; Yusuf, Fouza; Singh, Ashima; Taylor, Bradley; Woods, Katherine; Payne, Amanda B.; Peacock, Georgina; Schieve, Laura A. title: Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020 date: 2020-10-03 journal: Emerg Infect Dis DOI: 10.3201/eid2610.202792 sha: 6e3412e1323d6bbf1f1bf1270fea23fddd33b285 doc_id: 1028973 cord_uid: enkjcp8q Sickle cell disease (SCD) disproportionately affects Black or African American persons in the United States and can cause multisystem organ damage and reduced lifespan. Among 178 persons with SCD in the United States who were reported to an SCD–coronavirus disease case registry, 122 (69%) were hospitalized and 13 (7%) died. case-fatality rates. Given uncertainty in the sample representativeness and ongoing data reporting to the SECURE-SCD Registry, we view these data as a hypothesis-generating case series. Thus, we did not use statistical tests to assess the significance of differences in mortality rates by subgroup. As of May 21, 2020, a total of 178 COVID-19 cases were reported to the SECURE-SCD Registry among persons living in 22 states. The mean age of these case-patients was 28.6 years; 57% were female, and 80% were Black (Table) . A total of 76% of case-patients had sickle cell types HbSS or HbSβ 0 -thalassemia, which is consistent with estimates of SCD genotype distribution in the United States (11) . Recent (within the past 3 years) adverse events indicative of vasoocclusive crises were common among case-patients; 54% reported >3 pain episodes requiring hospitalization and 32% reported >1 acute chest syndrome episodes. ‡SCD genotypes are HbSS (homozygous for hemoglobin S, a severe phenotype associated with shortest survival); HbS 0 -thalassemia (compound heterozygous for hemoglobin S and  0 -thalassemia, clinically indistinguishable from HbSS); HbSC (heterozygous for hemoglobin S and hemoglobin C, usually moderate clinical severity); HbS+-thalassemia (heterozygous for hemoglobin S and reduced amounts of -globin, usually milder severity). §Acute chest syndrome is a multicausal pneumonia-like illness. ¶COVID-19 severity level classified as asymptomatic, no clinical signs or symptoms during the positive COVID-19 period; mild, symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, cough, sore throat, runny nose, and sneezing or gastrointestinal symptoms or digestive symptoms, such as nausea, vomiting, abdominal pain and diarrhea; moderate, pneumonia, with or without clinical symptoms, no hypoxia; severe, early respiratory symptoms or gastrointestinal symptoms followed by dyspnea and hypoxia (O2 saturations <92%); critical, acute respiratory distress syndrome, respiratory failure, encephalopathy, shock, coagulopathy, and multiorgan impairment (lung, heart, kidney, brain) that might be life threatening. Prevalence of pulmonary hypertension, previous stroke, renal disease, and use of chronic transfusion therapy were all >10%. A total of 6% of COVID-19 case-patients were asymptomatic, 54% had mild disease severity, 18% had moderate disease severity, 17% had severe disease severity, and 5% had critical disease severity. Nearly 90% of case-patients accessed care through an emergency department, 69% were hospitalized, 11% were admitted to an ICU, 6% required a ventilator, 38% required a transfusion, and 2% required dialysis. A total of 13 (7%) patients died (Table) . Their mean age was 38.5 years, and >90% were adults. Nearly 40% of deaths were among persons who had genotypes generally associated with milder SCD (types HbSC or HbSβ+-thalassemia). Patients who died had high proportions of frequent pain episodes in the previous 3 years (85%), pulmonary hypertension (39%), decreased renal function (23%), SCD nephropathy (15%), and overt stroke (31%). Of the 13 deaths, 8 were among persons who had severe or critical COVID-19; 5 deaths were observed in persons who had mild or moderate COVID-19. Our findings suggest that persons who have SCD and become infected with SARS-CoV-2 have a high risk for a severe disease course and a high case-fatality rate. Among confirmed COVID-19 case-patients reported to the registry, the 69% hospitalization rate, 11% ICU admission rate, and 7% mortality rate are alarming, given that the mean patient age was <40 years. Comparison to a previous report of COVID-19 in the general US population indicates that hospitalization, ICU admission, and case-fatality rates for persons with SCD could be much higher than persons of similar ages in the US population-at-large (12) . For example, COVID-19 case-fatality rates were reported as <1% for persons 20-44 years of age and for persons 45-54 years of age in the population-at-large (12) . These data should be considered in the context that these cases may not be representative of all COVID-19 cases among persons with SCD. There may be bias toward more severe cases in this registry; however, providers were asked to report all COVID-19 cases among their SCD patients. Also, whereas providers were specifically instructed to report only confirmed COVID-19 cases, further guidance was not provided on case confirmation, nor were laboratory testing results included in the registry; thus, we cannot rule out the possibility that a small number of suspected cases were erroneously reported. Our findings are consistent with expectations based on SCD pathophysiology. SCD can cause multisystem organ damage, life-long disability, and reduced lifespan. Nonetheless, in this case series, COVID-19 deaths occurred in persons who had severe and mild-to-moderate SCD genotypes. Also, deaths occurred in COVID-19 case-patients classified as having mild-to-moderate disease severity. We did not have data to assess whether this finding was caused in part by an impact of SARS-CoV-2 exacerbating preexisting cardiac or SCD concurrent conditions; further study is needed. Persons with SCD face socioeconomic and healthcare access disparities that might compound their already high risk for severe COVID-19 because of their underlying disease and concurrent conditions. SCD complications might negatively impact educational achievement and employment (13, 14) . Accessing appropriate healthcare is difficult given the lack of providers with SCD expertise. SCD patients might delay seeking care, and emergency department visits are high among this population that is placed at increased risk for poor health (14) . Our findings underscore the need to consider the unique circumstances faced by high-risk subgroups. SCD is one of many possible explanations for higher rates of illness and mortality from COVID-19 among Black populations in the United States. As with all high-risk groups, staying home, social distancing, and hand hygiene are necessary for persons with SCD (15), along with prompt care-seeking if COVID-19 is suspected or SCD complications arise. In addition, specific socioeconomic and healthcare access challenges that many persons with SCD face (i.e., social determinants of health) need to be considered in implementing prevention measures. Population estimates of sickle cell disease in the U.S Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease Defining sickle cell disease mortality using a population-based surveillance system Burden of influenza-related hospitalizations among children with sickle cell disease Pandemic influenza A (H1N1) virus infections in children with sickle cell disease COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome International COVID-19 PICU Collaborative. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units Epidemiology of COVID-19 among children in China Differences in the clinical and genotypic presentation of sickle cell disease around the world CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States Need for cognitive rehabilitation for children with sickle cell disease and strokes Social and behavioral factors in sickle cell disease: employment predicts decreased health care utilization CDC guidance for persons at higher risk of severe COVID-19 We thank the patients reported, the healthcare personnel who cared for them, and the providers and institutions who contributed to the SECURE-SCD Registry for participating in this study. Details for contributing providers and institutions are available at https://covidsicklecell.org.